Participating Companies

3T Biosciences
Provider of med­i­cal re­search and de­vel­op­ment fa­cil­i­ties in­tend­ed to of­fer im­munother­a­peu­tic ser­vices for can­cer-re­lat­ed dis­eas­es. The com­pany's fa­cil­i­ties in­cor­po­rate syn­thet­ic bi­ol­o­gy and ma­chine learn­ing to dis­cov­er nov­el tar­gets in or­der to cure can­cer and other T-cell me­di­at­ed dis­eas­es, en­abling pa­tients to re­ceive vari­ous can­cer dis­ease re­lat­ed treat­ments. [more in­for­ma­tion]
Artios Pharma
The Com­pany, found­ed by SV Health In­ves­tors in 2016, is led by an ex­pe­ri­enced sci­en­tif­ic and lead­er­ship team with proven ex­per­tise in DDR drug dis­cov­ery. [more in­for­ma­tion]
AsclepiX Therapeutics
Oph­thal­mol­o­gy com­pany us­ing com­pu­ta­tio­n­al bi­ol­o­gy to iden­ti­fy po­tent pep­tide reg­u­la­tors of vas­cu­lar home­os­ta­sis. The lead clin­i­cal can­di­date, in­te­grin reg­u­lat­ing pep­tide AX­T107 (ger­sizan­gi­tide), has a nov­el mech­anism of ac­tion that in­hibits neo­vas­cu­lariza­tion, re­duces vas­cu­lar perme­a­bil­i­ty and sup­press­es in­flam­ma­tion. In June 2020, Per­cep­tive Xon­toge­ny Ven­ture Fund led the $35 mil­lion Se­ries A fi­nanc­ing with par­ti­ci­pa­tion from ex­ist­ing in­ves­tors Rapha Cap­i­tal Ma­n­age­ment and Bar­er & Son Cap­i­tal. [more in­for­ma­tion]
Atom­wise is a tech­nol­o­gy-en­abled phar­ma­ceu­ti­cal com­pany us­ing AI to rev­o­lu­tion­ize small molecule drug dis­cov­ery. The Atom­wise team in­vent­ed the use of deep learn­ing for struc­ture-based drug de­sign en­abling a best-in-class AI dis­cov­ery en­gine, which is dif­fer­en­ti­at­ed by its abil­i­ty to find and op­ti­mize nov­el chem­i­cal mat­ter. [more in­for­ma­tion]
Caraway Therapeutics
Car­away Ther­a­peu­tics is a bio­phar­ma­ceu­ti­cal com­pany pur­su­ing nov­el ap­proach­es for the treat­ment of ge­net­i­cal­ly defined neu­rode­gen­er­a­tive and rare dis­eas­es. The Com­pany is a lead­er in the cutt­ing-edge sci­ence of ac­ti­vat­ing cel­lu­lar re­cy­cling pro­cess­es to clear tox­ic ma­te­rials and de­fec­tive cel­lu­lar com­po­nents by mo­d­u­lat­ing ly­so­so­mal func­tion. [more in­for­ma­tion]
Carisma Therapeutics Inc.
- CARIS­MA Ther­a­peu­tics Inc. is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Casma Therapeutics
The com­pany fo­cus­es on the au­topha­gy sys­tem to im­prove the cel­lu­lar pro­cess of clear­ing out un­want­ed pro­teins, or­ganelles, and in­vad­ing patho­gens, it al­so ar­rests or re­v­ers­es the pro­gres­sion of ly­so­so­mal stor­age di­s­or­ders, mus­cle di­s­or­ders, in­flam­ma­to­ry di­s­or­ders, and neu­rode­gen­er­a­tion, en­abling physi­cians to ad­dress un­met med­i­cal needs and to bring cures to pa­tients with se­ri­ous dis­eas­es. [more in­for­ma­tion]
Century Therapeutics
The com­pany's drugs are ge­net­i­cal­ly-en­gi­neered, iP­SC-de­rived im­mune ef­fec­tor cell prod­ucts de­signed to spe­cif­i­cal­ly tar­get he­ma­to­log­ic and solid can­cers by har­ness­ing the pow­er of adult stem cells, en­abling pa­tients to have ac­cess to cu­ra­tive ther­a­pies for can­cer. The funds will be used to ad­vance mul­ti­ple pro­grams in­to the clin­ic for he­ma­to­log­ic and solid ma­lig­nan­cies. [more in­for­ma­tion]
Confo Therapeutics
The com­pany is build­ing a port­fo­lio of pro­grams based on its pro­pri­e­tary tech­nol­o­gy which de­rives spe­cial­ized camelid sin­gle-do­main anti­bodies which sta­bi­l­ize G-pro­tein cou­pled re­cep­tors (GPCRs) in a con­for­ma­tion of in­ter­est for drug dis­cov­ery, en­abling the med­i­cal in­dus­try to be pro­vid­ed with nov­el path­way-se­lec­tive ag­on­ists for im­proved ther­a­peu­tic in­ter­ven­tion. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
Elevation Oncology
Our lead can­di­date, serib­an­tumab, in­hibits tu­mor growth driv­en by NRG1 fu­sions and is cur­rent­ly be­ing clin­i­cal­ly test­ed in the Phase 2 CRE­S­TONE study for pa­tients with tu­mors of any ori­gin that have an NRG1 fu­sion. [more in­for­ma­tion]
Eureka Therapeutics
The com­pany's plat­form is fo­cused on im­prov­ing the safe­ty pro­file of T cell ther­a­pies and de­vel­op­ing nov­el T cell ther­a­pies for the treat­ment of solid tu­mors, en­abling clients to avail a pipe­line of nov­el can­cer ther­a­peu­tics tar­get­ing in­tra­cel­lu­lar onco­genes as well as cell-sur­face anti­gens. [more in­for­ma­tion]
Fog Pharmaceuticals
Fog­Phar­ma's mis­sion is to dras­ti­cal­ly re­duce the bur­den of dis­ease on pa­tients and their fam­i­lies by in­vent­ing new types of drugs that squelch ab­nor­mal phy­si­o­log­i­cal pro­cess­es in ways pre­vi­ous­ly imagined but con­sid­ered unat­tain­able. [more in­for­ma­tion]
Op­er­a­tor of a bio­ther­a­peu­tics com­pany in­tend­ed to treat au­toim­mune, al­loim­mune, au­toin­flam­ma­to­ry, and al­ler­g­ic dis­eas­es. The com­pany de­vel­ops en­gi­neered reg­u­la­to­ry T cells (En­gTregs), thus help­ing clients by suc­cess­ful­ly res­tor­ing im­mune tol­er­ance and over­com­ing ma­jor lim­i­ta­tions in ex­ist­ing reg­u­la­to­ry T-cell ther­a­peu­tics. [more in­for­ma­tion]
Glycostem Therapeutics
Gly­costem Ther­a­peu­tics is a Dutch biotech com­pany. Gly­costem Ther­a­peu­tics is the trade name of the le­gal en­ti­ty IPD Ther­a­peu­tics BV, which has been estab­lished in De­cem­ber 2007. Gly­costem Ther­a­peu­tics has de­vel­oped the world's first GMP com­pliant NK-cell plat­form that is ready for in­dus­trial scale-up. [more in­for­ma­tion]
HemoShear Therapeutics
He­moS­hear Ther­a­peu­tics dis­cov­ers nov­el bi­o­log­i­cal tar­gets and ad­vances drug pro­grams to treat metabolic di­s­or­ders with sig­ni­f­i­cant un­met pa­tient need. The Com­pany's lead pro­grams in pro­pi­on­ic and methyl­malon­ic acidemia (rare in­born er­rors of metabolism) will en­ter phase 2 studies this year. [more in­for­ma­tion]
The com­pany al­so pro­vides un­par­al­leled com­pu­ta­tio­n­al bi­ol­o­gy ca­pa­bil­i­ties to lead­ing phar­ma­ceu­ti­cal and biotech­nol­o­gy com­pa­nies. Im­muneer­ing’s lead­ing pro­gram, a small molecule in IND-en­abling studies that tar­gets MEK, is pro­ject­ed to en­ter clin­i­cal trials in late 2021. Im­muneer­ing al­so has mul­ti­ple ad­di­tio­n­al pre­clin­i­cal pro­grams in on­col­o­gy, neu­ro­s­cience and im­muno-on­col­o­gy. [more in­for­ma­tion]
IN8bio, Inc. [INAB] $56 MM MCap
First com­pany to ad­vance ge­net­i­cal­ly-mod­i­fied gam­ma-del­ta T cells in­to clin­i­cal trials with its Del­tEx Plat­form, based on ex-vi­vo ex­pand­ed and ac­ti­vat­ed gam­ma-del­ta T cells. Two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials are un­der­way for lead prod­uct can­di­dates: INB-200 for new­ly di­ag­nosed glioblas­to­ma and INB-100 for acute leukemia. [more in­for­ma­tion]
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
Jasper Therapeutics
JJasper is a biotech­nol­o­gy com­pany fo­cused on de­vel­op­ing and com­mer­cial­iz­ing safer, more ef­fec­tive con­di­tion­ing agents to al­low for ex­pand­ed use of cu­ra­tive ther­a­py with stem cell tran­s­plan­ta­tion and gene ther­a­pies. Our goal is to make cures pos­si­ble with he­ma­topoi­et­ic cell tran­s­plan­ta­tion and gene ther­a­pies for all types of pa­tients, in­clud­ing chil­dren and the elder­ly. [more in­for­ma­tion]
Jna­na is fo­cused on de­vel­op­ing best-in-class ther­a­pies to treat a wide range of dis­eas­es, in­clud­ing rare ge­net­ic and im­mune-me­di­at­ed dis­eas­es in ad­di­tion to on­col­o­gy. [more in­for­ma­tion]
KAHR is de­vel­op­ing nov­el im­muno-on­col­o­gy fu­sion pro­teins. DSP107, is a CD47-41BB tar­get­ing com­pound aimed at tar­get­ing can­cer cells' in­nate de­fens­es and ac­ti­vat­ing lo­cal­ized re­sponse. Ac­ti­vat­ed path­ways in­clude in­nate and adap­tive im­mu­ni­ty. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Kriya Therapeutics
The com­pany us­es al­go­rith­mic tools, scal­able in­fras­truc­ture, and pro­pri­e­tary tech­nol­o­gy to op­ti­mize the ef­fi­ca­cy and dura­bil­i­ty of our gene ther­a­pies, there­by en­abling health­care in­sti­tu­tions to pro­vide trans­for­ma­tive new treat­ments for high­ly pre­va­lent and se­vere chron­ic dis­eas­es. [more in­for­ma­tion]
The com­pany's tech­nol­o­gy con­sists of an ad­vanced and pow­er­ful mo­d­u­lar RNA tar­get­ing-ef­fec­tor ap­proach to ad­dress the root cause of ge­net­ic dis­ease, en­abling med­i­cal prac­ti­tion­ers to op­ti­mize and ad­vance ther­a­peu­tic can­di­dates that are dist­inct from DNA-tar­get­ed ap­proach­es and nu­cle­ic acid-based RNA tar­get­ing. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in RNA ac­ti­va­tion (RNAa). Tech­nol­o­gy ca­pa­ble of drug­ging any pro­tein tar­get to in­crease na­t­u­ral pro­tein pro­duc­tion in pa­tients own cells. Im­muno-on­col­o­gy and rare dis­ease pipe­line with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (on­go­ing ran­domized Ph2 in 2L HCC, Ph1/1b in ad­vanced solid tu­mors re­sis­tant to an­ti-PD1), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Neurona Therapeutics
Our ini­tial aim is to gen­er­ate ther­a­peu­tic com­po­si­tions of a spe­cif­ic type of nerve cell (or neu­ron) for tar­get­ed de­liv­ery in­to the in­jured ner­vous sys­tem. Based on near­ly two de­cades of re­search, we be­lieve that par­tic­u­lar sub­pop­u­la­tions of neu­rons have the unique abil­i­ty to in­te­grate and re­pair dys­reg­u­lat­ed neu­ral cir­cuits. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Phase 2b ICO­NA NASH trial icos­abu­tate showed sig­ni­f­i­cant de­creas­es in NASH and fi­brot­ic bio­mark­ers and is sche­d­uled to read­out biop­sy da­ta in 1Q23. Two ad­di­tio­n­al SE­FAs (1024 and 6179) in Phase 1 clin­i­cal trials for pa­tients with dys­lipi­demia and the or­phan in­di­ca­tion IFALD, re­spec­tive­ly. [more in­for­ma­tion]
Omega Therapeutics
About Ome­ga Ther­a­peu­tics Ome­ga Ther­a­peu­tics is a pri­vate­ly held, de­vel­op­ment-stage biotech­nol­o­gy com­pany pi­oneer­ing the field of epige­nom­ic pro­gram­ming to pre­cise­ly reg­u­late and con­trol the hu­man genome to treat and cure dis­ease. [more in­for­ma­tion]
OncXerna Therapeutics
On­cX­er­na Ther­a­peu­tics of­fers a unique ap­proach to pre­ci­sion on­col­o­gy medicine based on a deep un­der­s­tand­ing of a pa­tient’s solid tu­mor mi­croen­vi­ron­ment and “dom­i­nant bi­ol­o­gy” at the RNA lev­el. [more in­for­ma­tion]
ONK Therapeutics Limited
The lead pro­gram, ONK­T101, is a du­al-tar­get­ed NK cell ther­a­py in­cor­po­rat­ing a CD19 CAR and TRAILv tar­get­ing DR5, in­tend­ed for the treat­ment of re­lapsed/re­frac­to­ry B cell ma­lig­nan­cies. [more in­for­ma­tion]
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
ReAlta Life Sciences
The com­pany's drugs have Com­ple­ment in­hi­bi­tion (C1), an­ti-in­flam­ma­to­ry, an­tioxi­dant and an­timi­cro­bial ca­pa­bil­i­ties to pro­vide game-chang­ing ther­a­py for mul­ti­ple un­met or un­der-ad­dressed med­i­cal needs, en­abling health­care pro­fes­sio­n­als to ad­dress life-threat­en­ing med­i­cal needs through ben­e­fi­cial in­hi­bi­tion of the Com­ple­ment Sys­tem and In­flam­ma­to­ry Mech­anisms. [more in­for­ma­tion]
Reistone Biopharma
Col­lab­o­ra­tion is in­te­gral to suc­cess, and we are cur­rent­ly look­ing for ei­ther part­n­er­ship to de­vel­op the AD and/or UC or CD in­di­ca­tions for phase 3 or out-li­cense the glob­al right ex­clud­ing Chi­na mar­ket. [more in­for­ma­tion]
Saniona [SANION:ST] SKr194 MM MCap
A re­search and de­vel­op­ment com­pany fo­cused on drugs for dis­eas­es of the cen­tral ner­vous sys­tem, au­toim­mune dis­eas­es, metabolic dis­eas­es and treat­ment of pain. The com­pany has a sig­ni­f­i­cant port­fo­lio of po­ten­tial drug can­di­dates at pre-clin­i­cal and clin­i­cal stage. [more in­for­ma­tion]
Scribe Therapeutics
Scribe Ther­a­peu­tics is a molec­u­lar en­gi­neer­ing com­pany fo­cused on build­ing best-in-class in vi­vo ther­a­pies to per­ma­nent­ly treat the un­der­ly­ing cause of dis­ease. [more in­for­ma­tion]
Sirnaomics [SRNAF]
De­vel­op­er of nov­el tar­get­ed ther­a­peu­tics in­tend­ed to treat crit­i­cal hu­man dis­eas­es. The com­pany's ther­a­peu­tics lev­er­age pro­pri­e­tary Po­lypep­tide Nano-Par­ti­cle (PNP) tech­nol­o­gy to ac­cess the tu­mor mi­cro-en­vi­ron­ment (TME), as well as vari­ous cell types in the liv­er, en­abling med­i­cal prac­ti­tion­ers to treat pa­tients ef­fec­tive­ly. er­ence tech­nol­o­gy. [more in­for­ma­tion]
The com­pany is gen­er­at­ing an ar­ray of "syn­thet­ic" cy­tokines that pos­sess greater cell se­lec­tiv­i­ty, bias cell sig­nal­ing, and/or pos­sess com­plete­ly new bi­o­log­i­cal ac­tiv­i­ties rel­a­tive to their na­tive coun­ter­part, en­abling po­ten­tial treat­ment of a range of dis­eas­es, from can­cer to au­toim­mune di­s­or­ders. [more in­for­ma­tion]
Triplet Therapeutics
Tri­plet is pur­su­ing a trans­for­ma­tive ap­proach to de­vel­op treat­ments for re­peat ex­pan­sion di­s­or­ders, a group of more than 40 known ge­net­ic dis­eas­es as­so­ci­at­ed with ex­pand­ed DNA nu­cleotide re­peats in­clud­ing Hunt­ing­ton’s dis­ease, my­o­ton­ic dys­tro­phy and vari­ous spino­cere­bel­lar ataxias. [more in­for­ma­tion]
Triumvira Immunologics
The com­pany's pro­pri­e­tary tech­nol­o­gy re­cruits the en­tire na­t­u­ral T-cell re­cep­tor and func­tions in­de­pen­dent of the Ma­jor His­to­com­pat­i­bil­i­ty Com­plex (MHC), po­ten­tial­ly al­low­ing for the de­vel­op­ment of bet­ter ther­a­pies for a broad­er range of pa­tients with solid or liquid ma­lig­nan­cies and with dis­eas­es other than can­cer, there­by pro­vid­ing med­i­cal prac­ti­tion­ers and pa­tients with new hope to deal with life-threat­en­ing dis­eas­es. [more in­for­ma­tion]
Tvardi Therapeutics
The com­pany's ser­vices fo­cus on the key sig­nal­ing molecule, STAT3, which is po­si­tioned at the in­ter­sec­tion of many path­ways con­trolling gene net­works in­te­gral to the sur­vi­val and im­mune se­ques­tra­tion of can­cer cells as well as to the patho­ge­n­e­sis of many in­flam­ma­to­ry and fi­brot­ic con­di­tions, en­abling pa­tients to get medicines for the treat­ment of breast can­cer and lung can­cer. [more in­for­ma­tion]
Ver­san­tis is a phase 2a phar­ma­ceu­ti­cal com­pany de­vel­op­ing a new gen­er­a­tion of or­phan medicines to rev­o­lu­tion­ize the care of pa­tients with liv­er dis­eas­es nd ul­tra-rare pe­di­a­tric urea cy­cle di­s­or­ders. Ver­san­tis is de­vel­op­ing its lead can­di­date, VS-01, as a first-line med­i­ca­tion for the acute sup­port of cir­rhot­ic and metabolic de­com­pen­sa­tions. [more in­for­ma­tion]
Verve Therapeutics
Verve is de­vel­op­ing medicines, ad­min­is­tered once in life, to safe­ly ed­it the genome of adults and mim­ic na­t­u­ral­ly oc­cur­ring gene variants to per­ma­nent­ly low­er LDL choles­terol and trig­lyc­eride lev­els and there­by treat coro­nary heart dis­ease. [more in­for­ma­tion]
Xilio Therapeutics
Xilio Ther­a­peu­tics is a biotech­nol­o­gy com­pany ad­vanc­ing next-gen­er­a­tion can­cer im­munother­a­pies de­signed to im­prove pa­tient out­comes by un­leash­ing the pow­er of the im­mune sys­tem se­lec­tive­ly at the site of the tu­mor. [more in­for­ma­tion]